OSUR Related Analyst Ratings
-
Jefferies Assumes OraSure Technologies (OSUR) at Buy
-
Stephens Starts OraSure Technologies (OSUR) at Overweight
-
Janney Montgomery Scott Starts OraSure Technologies (OSUR) at Buy
-
Jefferies Trims Price Target on OraSure Technologies (OSUR)
-
Mizuho Securities Starts OraSure Technologies (OSUR) at Buy
-
JMP Securities Resumes OraSure Technologies (OSUR) at Market Outperform
-
Raymond James Starts OraSure Technologies (OSUR) at Market Perform
-
Celebrity Magic Johnson Teams with OraSure (OSUR) to Launch In-Home HIV Test
-
Cowen Starts OraSure Technologies (OSUR) at Neutral
-
Citi Starts OraSure Technologies (OSUR) at Buy
-
Jefferies Starts OraSure Technologies (OSUR) at Buy
-
In-Home HIV Test Could Be Hit, Barrington Research Upgrades OraSure Technologies (OSUR) to Outperform
-
Canaccord Genuity Maintains a 'Buy' on OraSure Technologies (OSUR); Q2 Preview: Build on its Momentum
-
Canaccord Genuity Reiterates a 'Buy' on OraSure Technologies (OSUR); OraQuick HIV-OTC Test in 30,000 Locations
-
Barrington Research Downgrades OraSure Technologies (OSUR) to Market Perform; Closer Look at Valuation
-
Canaccord Genuity Reiterates a 'Buy' on OraSure Technologies (OSUR); Awaiting Approval of HIV-OTC Test
-
Canaccord Genuity Reiterates a 'Buy' on OraSure Technologies (OSUR); Expect Adoption of HCV Testing Guidelines
-
Canaccord Genuity Reiterates a 'Buy' on OraSure Technologies (OSUR); FDA Panel Supports HIV-OTC
-
Canaccord Genuity Maintains a 'Buy' on OraSure Technologies (OSUR); Focus on 2012 Catalysts
-
Benchmark Starts Chembio Diagnostics (CEMI) at Speculative Buy; Potential Over-the-Counter HIV Resting Market
-
Canaccord Genuity on Life Sciences/Biomedical Devices & Services: Pipelines To Lead Way Through Q1
-
RBC Capital Starts OraSure Technologies (OSUR) at Outperform
-
Canaccord Genuity Reiterates a 'Buy' on OraSure Technologies (OSUR); Meeting Confirms Urgent Need for Rapid Testing
-
JMP Securities Starts OraSure Technologies (OSUR) at Market Outperform
-
McNicoll Lewis & Vlak Upgrades OraSure Technologies (OSUR) to Buy
-
Canaccord Genuity Reiterates a 'Buy' on OraSure (OSUR); Congress Shows Support
-
Canaccord Genuity Reiterates a 'Buy' on OraSure Technologies (OSUR); Meeting With Management
-
Canaccord Genuity Reiterates a 'Buy' on OraSure Technologies (OSUR); Catalysts on the Horizon
-
McNicoll Lewis & Vlak Downgrades OraSure Technologies (OSUR) to Hold
-
ThinkEquity Starts OraSure Technologies (OSUR) at Buy
-
Canaccord Genuity reiterates a 'Buy' on OraSure Technologies (OSUR); Remain Bullish After Meeting with Management
-
Canaccord Genuity on Life Sciences/Biomedical Devices and Services: 2012 Best Ideas: OraSure (OSUR) and Cepheid (CPHD)
-
Canaccord Genuity Reiterates a 'Buy' on OraSure Technologies (OSUR); HCV Study May Boost Guidelines
-
Canaccord Genuity Reiterates a 'Buy' on OraSure Technologies (OSUR); Q3 Good but Product Approvals Nearing
-
Canaccord Genuity Reiterates a 'Buy' on OraSure Technologies (OSUR); HIV-OTC Timeline May Improve
-
Canaccord Genuity Reiterates a 'Buy' on OraSure Technologies (OSUR); HCV Update
-
Canaccord Genuity Reiterates a 'Buy' on OraSure Technologies (OSUR); Identifies MDx Entry Point
-
Canaccord Genuity Reiterates a 'Buy' on OraSure Technologies (OSUR); Attention Shifts to HCV Waiver
-
ThinkEquity Starts NuVasive (NUVA), OraSure (OSUR), Stereotaxis (STXS), Natus (BABY) at Buy
-
McNicoll Lewis & Vlak Starts OraSure Technologies (OSUR) at Buy, Positive Up Coming Quarters
-
Canaccord Genuity on Life Sciences: Biomedical Devices and Services - Japan Crisis: What Is The Impact on Diagnostic Companies?
-
Canaccord Genuity Reiterates a 'Buy' on OraSure Technologies (OSUR); Another Regulatory Milestone
-
Canaccord Genuity Reiterates a 'Buy' on OraSure Technologies (OSUR); Q4 In-Line, but Pipeline Catalysts Key to 2011
-
UPDATE - Barrington Research Initiates Coverage on OraSure Technologies (OSUR) with an Outperform; Inexpensive at Current Level
-
Barrington Research Starts OraSure Technologies (OSUR) at Outperform
-
Canaccord Genuity Reiterates a 'Buy' on OraSure Technologies (OSUR); Pipeline Catalysts Progressing
-
Canaccord Genuity Initiates Coverage on Life Sciences – Biomedical Devices and Services Stocks
-
Canaccord Genuity Starts OraSure Technologies (OSUR) at Buy, Price Target $8
-
Needham & Company Reiterates a 'Buy' on OraSure Technologies (OSUR); 3Q10 Beats Estimates On Strong Public Health Orders
-
Needham & Company Reiterates a 'Buy' Rating on OraSure Technologies (OSUR); National HIV/AIDS Strategy May Expand Testing
Back to OSUR Stock Lookup
